Display Settings:

Format

Send to:

Choose Destination
    Lung. 2009 May-Jun;187(3):149-52. Epub 2009 Feb 27.

    Stabilization of lung function and clinical symptoms in a patient with cystic fibrosis (CF) after institution of infliximab: a monoclonal antibody that binds tumor necrosis factor alpha.

    Source

    Division of Pulmonary/Critical Care and Sleep Medicine, Memorial Hospital of Rhode Island, 111 Brewster Street, Pawtucket, RI 02860, USA. Brian_Casserly@brown.edu

    Abstract

    The most characteristic feature of airway inflammation in cystic fibrosis (CF) is the persistent infiltration of massive numbers of neutrophils. Although inflammation is primarily a protective response to injury, it has the potential to cause considerable harm when it is excessive. Recent recognition of the prominent role of inflammation has prompted the investigation of treatments designed to control inflammation in the CF lung. We report a 35-year-old man with abrupt stabilization of his rapidly progressive CF and forced expiratory volume (FEV1) after starting infliximab for his rheumatoid arthritis. This effect was sustained for 8 years while continuing to use twice-monthly infliximab.

    PMID:
    19247707
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Click here to read

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk